Mylan and its CEO Heather Bresch are under fire. It raised the price of its EpiPen product — an essential protection for people with life threatening allergies — by a factor of five in the last eight years. Mylan’s statement defending itself clarifies what it’s doing — providing rebates — but evades the main issue of … Continued